New service complements June 1 opening of CCCN pulmonary division
Las Vegas (June 8, 2015) — Comprehensive Cancer Centers of Nevada (CCCN), a practice in The US Oncology Network, announced today the introduction of a new lung cancer screening service – a low-dose CT scan for targeted patients. The screening announcement accompanies the opening of CCCN’s new pulmonary division: Lung Center of Nevada, a division of Comprehensive Cancer Centers of Nevada.
These proactive efforts allow CCCN to continue to broaden its services while offering patients with lung and bronchus cancer a seamless flow of care. Lung and bronchus cancers remain the leading cause of cancer deaths in Nevada and, in 2015, are estimated to kill more than 1,700 Nevadans.
Lung cancer screening is an option for CCCN patients of two high-risk groups; patients who are 55 years and older who have smoked for 30 or more pack years. A pack year is defined as 20 cigarettes smoked every day for one year. The second high-risk group consists of patients 50 years and older who have smoked for 20 or more pack years. Patients with select risk factors include those who have been exposed to radon, have worked in a chemical-heavy environment or have a family history of lung cancer or a related disease, such as COPD or pulmonary fibrosis.
Earlier this year, the Centers for Medicare and Medicaid Services announced approved Medicare coverage for lung cancer screening in high-risk patients by low-dose CT, marking the first time the government program will cover annual screenings. Other insurance plans may authorize coverage depending on certain diagnosis and clinical requirements. A CCCN insurance specialist can help determine if the patient’s insurance will cover the cost of service.
The CT scan service is currently available at CCCN’s Central Valley clinic, located at 3730 S. Eastern Ave., and will become available at CCCN’s Southwest and Henderson (10001 S. Eastern Ave., Henderson, NV 89052) locations by the end of August.
Lung Center of Nevada, a division of Comprehensive Cancer Centers of Nevada, will provide evaluation, diagnosis and referrals for treatment options to patients with lung and bronchus cancer. The new division will also treat various lung diseases and sleep disorders including asthma, emphysema, chronic bronchitis, chronic cough, nicotine dependence, snoring, insomnia and obstructive sleep apnea.
For more than 35 years, CCCN physicians have studied, tested new therapies for and treated patients with lung and bronchus cancer. During the past year, the practice has seen 1,435 patients with lung cancer, 789 of whom were newly diagnosed with the disease. In affiliation with The US Oncology Network, CCCN is Nevada’s foremost leader in clinical research trials conducting more than 170 Phase I, II and III trials each year, of which include trials specific to lung cancer.
Physicians joining the CCCN team are John (Jack) Collier, MD, FCCP, DABSM; James Hsu, MD, FCCP, DABSM; George Tu, MD, FCCP, DABSM; John Wojcik, MD, FCCP, DABSM; and Ralph Nietrzeba, MD, FCCP, FACP.
Lung Center of Nevada, a division of Comprehensive Cancer Centers of Nevada, has two locations in Southern Nevada, at: 9280 West Sunset Road, Suite 312 in the Southern Hills Hospital Medical Office Building and 3150 North Tenaya Way, Suite 125 in the Mountain View Hospital Medical Office Building.
About Comprehensive Cancer Centers of Nevada and The US Oncology Network
Comprehensive Cancer Centers of Nevada (CCCN) is an award-winning multidisciplinary oncology group comprising medical oncology, hematology, radiation oncology, breast surgery and clinical research, with 11 treatment centers and offices throughout Southern Nevada. For more than 35 years, the practice has provided oncology services to patients in and out of state with a specialized physician and nursing staff. CCCN offers state-of-the-art technologies, latest advancements in cancer treatment and groundbreaking clinical research through its national affiliation with The US Oncology Network. The practice participates in more than 170 Phase I, Phase II and Phase III clinical research studies each year and has played a role in developing 54 FDA-approved cancer therapies. For more information, visit the company’s web site at www.cccnevada.com, and follow the practice on Facebook at www.facebook.com/cccnevada and Twitter @CCCNevada.